Sysmex (OTCMKTS:SSMXY) Shares Gap Down – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $8.80, but opened at $8.26. Sysmex shares last traded at $8.54, with a volume of 2,860 shares changing hands.

Analyst Ratings Changes

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Sysmex Price Performance

The company has a 50 day simple moving average of $8.72 and a 200-day simple moving average of $9.11. The stock has a market cap of $5.29 billion, a price-to-earnings ratio of 22.11 and a beta of 1.10. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Research analysts expect that Sysmex Corporation ADR will post 0.42 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.